Oncology

The associate professor of medicine at University of Colorado discussed how the field has shifted to support the growing use of CAR Ts and progress to come.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The Prescription Drug User Fee Act (PDUFA) target action date is August 4, 2024.

Review top news and interview highlights from the week ending July 5, 2024.

The associate professor of medicine at University of Colorado discussed a post hoc analysis study on subgroup analyses of liso-cel response.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Patients in FUMANBA-2 received eque-cel after being ineligible for ASCT after 4 cycles of induction therapy.

Eight patients receiving either TSC-100 or TSC-101 have been disease-free for a median of 10 months of follow-up.

Review top news and interview highlights from the week ending June 28, 2024.

Notably, 1 patient treated in the trial died of respiratory failure, but it is not clear whether the death was related to LYL797.

The associate professor of medicine at University of Colorado discussed data in the primary relapsed LBCL setting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The company has dosed the sixth patient in the study, and expects to move onto the third cohort pending continued safety at 1 month posttreatment.

The professor from Cedars Sinai discussed further research being conducted in the field after lifileucel’s approval.

With the company having recently announced that it intends to expand the clinical trial with a new cohort, CGTLive® has decided to take a closer look at this ongoing study.

Review top news and interview highlights from the week ending June 21, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The responses seen in the 9 patients included 3 complete responses (CRs), 2 very good partial responses, and 4 partial responses.

In terms of safety, SNK02 was characterized as “well-tolerated”.

Earlier and prophylactic interventions have enabled low rates and severity of AEs in recent years of administration.

On the other hand, enhanced lymphodepletion increased incidence and severity of CRS and infection.

The scientist from Krembil Research Institute shared takeaways from the session she chaired.

Review top news and interview highlights from the week ending June 14, 2024.

The subgroup analysis also looked at safety outcomes.

The medical oncologist and clinical director of Myeloma Cellular Therapies at Dana-Farber Cancer Institute emphasized promising safety in patients with high-risk disease.

Among 10 patients who were treated with INB-100 in the trial, all 10 (100%) maintained their state of CR at 12 months or more posttreatment.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The cofounder and chief scientific officer at Earli discussed the company’s unique approach to cancer diagnosis.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.